10-minute watch
EHA: How is CAR T evolving?
Why should CAR T be used earlier in R/R DLBCL?
Dr Claire Roddie
11-minute watch
EHA: How is CAR T evolving?
What does the future hold for CAR T manufacturing?
Dr Carl June
13-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
CAR T survivorship and summary
Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques
18-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Choosing CAR T with curative intent
Dr Natasha Kekre
10-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Delivering CAR T
Dr Pierre Sesques
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Planning ahead for 2L
Prof. Graham Collins, Dr Mariana Bastos-Oreiro
14-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist
Ms Surabhi Chaturvedi, Dr Wendy Osborne
24-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
How can we bring CAR T’s curative potential to more patients?
Ms Surabhi Chaturvedi, Dr Suzanne van Dorp
14-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
What is the most appropriate treatment choice in 2L LBCL? A case-based approach
Dr Wendy Osborne
20-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
Why has CAR T become the SoC in 2L LBCL?
Dr Anna Sureda
15-minute watch
EU CAR T: Kite symposium
How can we improve survival outcomes in R/R LBCL?
Dr Cathy Burton
15-minute watch
EU CAR T: Kite symposium
How has CAR T changed survival outcomes in LBCL so far?
Dr Pere Barba, Prof. Peter Vandenberghe
5-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy
How can we address reimbursement challenges for CAR T?
Adam Hutchings
4-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy
Why is timely reimbursement of CAR T important for our patients?
Anuradha Rajapakse
3-minute watch
EU CAR T: Expert Perspective
Secondary malignancies after Car T-cell therapy
Dr Anna Sureda
3-minute watch
ASH: Expert perspective
DESCART registry data in 2L DLBCL (vidéo en français)
Dr Gabriel Brisou
2-minute watch
ASH: Expert perspective
ASTCT Clinical Practice Guidelines for DLBCL
Dr Olalekan Oluwole
3-minute watch
ASH: Expert perspective
Outpatient management in CAR T-cell therapy
Dr Olalekan Oluwole
5-minute watch
ASH: Expert perspective
Updates on ZUMA-1, ZUMA-7 and RWE on the use of CAR T in DLBCL
Dr Jason Westin
2-minute watch
ASH: Expert perspective
Sequencing of bispecific antibodies and CAR T cell therapy
Dr Matthew Frigault
3-minute watch
ASH: Expert perspective
If they RECUR, refer – the importance of early patient identification
Dr Michael Bishop
5-minute watch
ASH: Expert perspective
Real-world evidence on the use of CAR T in R/R adult ALL
Dr Lori Muffly
3-minute watch
Prof. Graham Collins: Expert perspective
Centre qualification process
Prof. Graham Collins
1-minute watch
Prof. Graham Collins: Expert perspective
Referral considerations
Prof. Graham Collins
4-minute watch
Prof. Graham Collins: Expert perspective
RTC and QTC collaborations
Prof. Graham Collins
4-minute watch
Prof. Graham Collins: Expert perspective
RTC and QTC relationships
Prof. Graham Collins
5-minute watch
Prof. Graham Collins: Expert perspective
Preparing the patient for CAR T
Prof. Graham Collins
3-minute watch
ASCO, EHA & ICML: Expert perspective
Emerging practice-changing data in haematological malignancies
Prof. Max Topp
2-minute watch
ASCO, EHA & ICML: Expert perspective
The effect of bendamustine bridging on CAR T outcomes
Dr Gloria Iacoboni
4-minute watch
ASCO, EHA & ICML: Expert perspective
Highlights of summer congresses
Dr Matthew Lunning
2-minute watch
ASCO, EHA & ICML: Expert perspective
Is there a role for consolidation radiotherapy in primary mediastinal large B‑cell lymphoma?
Dr Wendy Osborne
4-minute watch
ASCO, EHA & ICML: Expert perspective
Updates on front‑line management in NHL
Prof. Christopher Fox
10-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
CAR T in 2L DLBCL: A case study
Dr Jason Westin
23-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Frederick Locke, Dr Matthew Lunning
9-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
Defining the unmet need in 2L DLBCL
Dr Michael Dickinson
1-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
Series trailer
Dr Anna Sureda, Dr Frederick Locke, Dr Jason Westin, Dr Matthew Lunning, Dr Michael Dickinson
5-minute watch
ICML: Evolving survival outcomes with CAR T in 2L DLBCL
Welcome & introduction
Dr Anna Sureda
5-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Close
Prof. Marie José Kersten
10-minute watch
ASCO, EHA & ICML: Expert perspective
Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data
Dr Bijal Shah
3-minute watch
ASCO, EHA & ICML: Expert perspective
Real-world data supporting CAR T‑cell therapy in non‑Hodgkin's lymphoma
Dr Robin Sanderson
3-minute watch
ASCO, EHA & ICML: Expert perspective
CAR T‑cell therapy in the management of primary CNS lymphoma
Dr Kate Cwynarski
3-minute watch
ASCO, EHA & ICML: Expert perspective
Latest data from CAR T‑cell therapy and bispecific antibody use in DLBCL
Dr Michael Dickinson
2-minute watch
ASCO, EHA & ICML: Expert perspective
ZUMA-7: My key takeaways
Dr Miguel-Angel Perales
3-minute watch
ASCO, EHA & ICML: Expert perspective
ZUMA-7: What is the Q-TWiST analysis?
Dr Miguel-Angel Perales
3-minute watch
ASCO, EHA & ICML: Expert perspective
ZUMA-7: Survival outcomes with axicabtagene ciloleucel in 2L DLBCL
Prof. Marie José Kersten
10-minute watch
ICML: How do we improve outcomes for underserved populations with B-cell malignancies?
Are we ensuring diversity and inclusion in clinical studies?
Dr Mark Bishton
10-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Case study 4: CAR T in the outpatient setting
Dr Olalekan Oluwole
6-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Case study 3: Achieving a CR after bridging and the use of CAR T
Dr Miguel-Angel Perales
5-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Case study 2: Managing bulky disease
Dr Wendy Osborne
11-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Case study 1: Hard to manage ICANS
Prof. Christopher Fox
7-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Welcome, introduction and challenges in R/R DLBCL: Overview
Prof. Marie José Kersten
1-minute watch
ICML: Improving outcomes in R/R DLBCL: Learning from challenging cases
Series trailer
Prof. Christopher Fox, Prof. Marie José Kersten, Dr Miguel-Angel Perales, Dr Olalekan Oluwole, Dr Wendy Osborne
5-minute watch
ASCO, EHA & ICML: Expert perspective
Supporting patients and caregivers through their CAR T‑cell therapy journey
Ms Lorna Warwick
8-minute watch
ASCO, EHA & ICML: Expert perspective
What is the role of patient prehabilitation prior to CAR T‑cell therapy?
Dr Keith Wilson
10-minute watch
EHA: Tracing the steps to CAR T and beyond
What are the steps to CAR T-cell infusion?
Dr Nicolaus Kröger, Dr Robin Sanderson
7-minute watch
EHA: Tracing the steps to CAR T and beyond
How do you identify the appropriate CAR T patient?
Dr Nicolaus Kröger, Dr Sridhar Chaganti
13-minute watch
EHA: Managing R/R adult ALL in the CAR T era
Understanding the role of CAR T in R/R adult ALL
Dr Bijal Shah
11-minute watch
EHA: Navigating CAR T in 2L DLBCL
How has CAR T changed the second-line DLBCL treatment landscape? Further studies
Prof. Bertram Glaß
11-minute watch
EHA: Navigating CAR T in 2L DLBCL
How has CAR T changed the second-line DLBCL treatment landscape?
Dr Olalekan Oluwole
16-minute watch
EHA: Tracing the steps to CAR T and beyond
How should we manage our patients post CAR T?
Dr Gloria Iacoboni, Dr Nicolaus Kröger
6-minute watch
EHA: Managing R/R adult ALL in the CAR T era
Expert perspectives: Exploring CAR T treatment approaches in R/R adult ALL – Case study 3
Dr Bijal Shah
4-minute watch
EHA: Managing R/R adult ALL in the CAR T era
Expert perspectives: Exploring CAR T treatment approaches in R/R adult ALL – Case study 2
Dr Florence Rabian
4-minute watch
EHA: Managing R/R adult ALL in the CAR T era
Expert perspectives: Exploring CAR T treatment approaches in R/R adult ALL – Case study 1
Dr Florence Rabian
7-minute watch
EHA: Navigating CAR T in 2L DLBCL
CAR T in 2L DLBCL: A case study
Dr Eva Wagner-Drouet
11-minute watch
EHA: Navigating CAR T in 2L DLBCL
Defining the unmet need in second-line DLBCL
Dr Keith Wilson
1-minute watch
EHA: Managing R/R adult ALL in the CAR T era
Series trailer
Dr Bijal Shah, Dr Florence Rabian, Prof. Max Topp
1-minute watch
EHA: Tracing the steps to CAR T and beyond
Series trailer
Dr Gloria Iacoboni, Dr Nicolaus Kröger, Dr Robin Sanderson, Dr Sridhar Chaganti
2-minute watch
EHA: Tracing the steps to CAR T and beyond
Welcome and introduction
Dr Sridhar Chaganti
1-minute watch
EHA: Navigating CAR T in 2L DLBCL
Series trailer
Prof. Bertram Glaß, Dr Eva Wagner-Drouet, Dr Keith Wilson, Ms Lorna Warwick, Dr Olalekan Oluwole
5-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
Redefining the treatment paradigm in 2L DLBCL
Dr Eva Wagner-Drouet
16-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
How has CAR T changed the 2L DLBCL treatment landscape?
Dr Miguel-Angel Perales
1-minute watch
EBMT: How has CAR T changed the 2L DLBCL treatment landscape?
Series trailer
Dr Eva Wagner-Drouet, Dr Miguel-Angel Perales
20-minute watch
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL
CAR T‑cell therapy is the most recent therapy with curative potential for the treatment of R/R DLBCL
Prof. Max Topp, Dr Miguel-Angel Perales
24-minute watch
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL
CAR T should be used as early as possible in the treatment of R/R DLBCL
Prof. Catherine Thieblemont, Dr William Townsend
6-minute watch
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL
Welcome and introduction
Prof. Catherine Thieblemont
1-minute watch
EBMT: Debate: CAR T vs. BsAbs in R/R DLBCL
Series trailer
Prof. Catherine Thieblemont, Prof. Max Topp, Dr Miguel-Angel Perales, Dr William Townsend
12-minute watch
EHA: Tracing the steps to CAR T and beyond
Treatment selection in 2L DLBCL
Dr Sridhar Chaganti
Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023